Loading stock data…
Niagen Bioscience, Inc. (NAGE)
$3.30-0.12 (-3.51%)
Market ClosedLast close Jun 29
Niagen Bioscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Niagen Bioscience, Inc. in the Healthcare sector is trading at $3.30 with a market capitalization of $307M. Wall Street consensus targets $12.60 (5 analysts), implying a +281.8% move over the next 12 months. The stock is currently near its 52-week low of $3.27, remaining 43.1% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +281.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $31.47M↓ | $33.84M↓ | $33.99M↑ | $31.12M↑ | $30.48M |
| Gross Profit | $19.98M↓ | $21.70M↓ | $21.93M↑ | $20.23M↑ | $19.33M |
| Operating Income | $1.58M↓ | $2.10M↓ | $4.24M↑ | $3.19M↓ | $4.77M |
| Net Income | $6.32M↑ | $4.13M↓ | $4.58M↑ | $3.61M↓ | $5.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that con...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$307.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.38
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.64%
Volume
Today's trading volume
695,049
Recent News
Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications
Niagen Bioscience Inc. (NASDAQ:NAGE) is one of the high-growth micro-cap stocks to buy now. On June 2, Niagen Bioscience Inc. (NASDAQ:NAGE) renamed the ChromaDex External Research Program (CERP) to the Niagen Research Program to underscore its renewed focus on advancing the understanding and applications of NAD+. Over the years, the company has focused on building […]
Niagen Bioscience (NAGE) Stock Sees Split Analyst Revisions As Price Targets Fall
Niagen Bioscience is back in focus after analysts cut their combined price targets by US$5 while still holding the fair value estimate steady at US$12.60. The adjustment reflects fresh scrutiny of the assumptions sitting behind that fair value, as research teams fine tune their models and weigh both the long term opportunity and the risks around it. As you read on, you will see how these shifting targets shape the evolving story around Niagen Bioscience and what to watch next in the analyst...
Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program
Niagen Bioscience (NAGE) recently renamed its ChromaDex External Research Program as the Niagen Research Program, tying its identity more closely to NAD+ science and more than 175 supported studies worldwide. See our latest analysis for Niagen Bioscience. The renaming of the research program comes at a time when Niagen Bioscience’s share price has been under pressure, with a 30 day share price return down 27.39% and year to date share price return down 44%. However, the 3 year total...
How The Niagen Bioscience (NAGE) Investment Story Is Evolving Without New Analyst Signals
Niagen Bioscience’s latest update leaves its price target unchanged, giving you a clear reference point without any fresh shifts in analyst expectations. With no new analyst commentary provided alongside this update, the focus stays squarely on how the existing outlook might fit into your own view of the stock. Read on to see practical ways to track changes like this and keep up with the evolving narrative around Niagen Bioscience over time. Stay updated as the Fair Value for Niagen...
3 Growth Companies With High Insider Ownership And 15% Revenue Growth
The market has been flat in the last week but is up 27% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context, growth companies with high insider ownership and significant revenue expansion can be particularly appealing as they often signal strong internal confidence and potential for sustained performance.